Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.

The Journal of rheumatology - 1 Jun 2017

Ke Ching-Hua, Chung Wen-Hung, Wen Yen-Hsia, Huang Yaw-Bin, Chuang Hung-Yi, Tain You-Lin, Wang Yu-Ching Lily, Wu Cheng-Chih, Hsu Chien-Ning

Abstract excerpt

OBJECTIVE: Patients with an HLA-B*58:01 allele have an increased risk of developing severe cutaneous adverse drug reactions (SCAR) when treated with allopurinol. Although one-off pharmacogenetic testing may prevent life-threatening adverse drug reactions, testing prior to allopurinol initiation incurs additional costs. The study objective was to evaluate the cost-effectiveness of HLA-B*58:01 screening compared...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allopurinol
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genetic Testing

Share to Genotype

Share to Gout Suppressants

Share to HLA-B Antigens

Share to Pharmacogenetics

Source

Identifiers

PMID: 28365572
DOI: 10.3899/jrheum.151476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness Analysis for Genotyping before Allopurinol Treatment to Prevent Severe Cutaneous Adverse Drug Reactions.PMID 28365572Read ↗

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?Semantic proximity Read ↗

Cost-effectiveness analysis of HLA-B5801 genotyping in the treatment of gout patients with chronic renal insufficiency in Korea.Semantic proximity Read ↗

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing.Semantic proximity Read ↗

Impact of HLA-B*58:01 allele and allopurinol-induced cutaneous adverse drug reactions: evidence from 21 pharmacogenetic studies.Semantic proximity Read ↗

Global Frequencies of Clinically Important HLA Alleles and Their Implications For the Cost-Effectiveness of Preemptive Pharmacogenetic Testing.Semantic proximity Read ↗

HLA-B*58:01 is an Incomplete Predictor of Allopurinol-Induced Severe Cutaneous Adverse ReactionsSemantic proximity Read ↗

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Semantic proximity Read ↗

Pharmacogenomics of drug-induced hypersensitivity reactions: challenges, opportunities and clinical implementation.Semantic proximity Read ↗

Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population.Semantic proximity Read ↗

Pharmacogenetics of allopurinol--making an old drug safer.Semantic proximity Read ↗

Human leukocyte antigen (HLA) pharmacogenomic tests: potential and pitfalls.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.